iSpecimen Inc. Reports 85% Revenue Decline and Increased Net Loss in Latest 10-Q Filing

iSpecimen Inc. reported significant financial challenges in its latest 10-Q filing for the quarter ending March 31, 2026. The company generated revenue of $156,009, a stark decline of approximately 85% from $1,057,510 in the same quarter of the previous year. This drop was attributed to a 61% decrease in specimen count, which fell from 2,309 to 890 specimens, and a corresponding reduction in the average selling price per specimen. The company's operating expenses remained relatively stable, totaling $2,694,412, compared to $2,695,899 in the prior year, with notable increases in sales and marketing expenses.

The company's net loss for the quarter was $2,275,221, compared to a loss of $1,658,396 in the previous year, marking a 37% increase in losses. This increase was primarily driven by the substantial decline in revenue, despite a decrease in costs associated with revenue generation. iSpecimen's cash and cash equivalents also saw a significant reduction, dropping to $2,818,989 from $6,880,835 at the end of the previous fiscal year, reflecting a decrease of 59%.

In terms of strategic developments, iSpecimen has been actively working to streamline operations and reduce costs. The company has implemented workforce reductions that have led to a 70% decrease in monthly compensation costs and a 36% reduction in technology costs during the first quarter of 2026 compared to the same period in 2025. Additionally, the company has focused on enhancing its technology platform, capitalizing $700,000 in internally developed software costs as part of its digital transformation efforts.

Operationally, iSpecimen has faced challenges in customer engagement, with one customer accounting for 54.42% of total revenues in the latest quarter. The company has also been affected by broader economic conditions, which have led to increased allowances for doubtful accounts due to customer liquidity issues. The company is taking steps to improve its financial position, including reevaluating pricing strategies and enhancing internal communications to accelerate the sales cycle.

Looking ahead, iSpecimen's management has expressed uncertainty regarding its ability to continue as a going concern, citing the need for additional working capital and the potential for further operational scaling down if revenue generation does not improve. The company is focused on generating additional revenues and managing expenses to navigate its financial challenges, but acknowledges that many factors influencing its success are beyond its control.